Q-omics provides the consensus-scored OR5AP2 profile across patient tissues and cancer cell-line models. OR5AP2 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, OR5AP2 is differentially expressed in 1, with the highest sampling consensus in BRCA. Additionally, OR5AP2 RNA expression shows 6,379 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, BRCA, and STAD as cancer lineages where OR5AP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR5AP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR5AP2 survival associations across molecular data types. OR5AP2 RNA expression shows survival associations in the most cancer types (11), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR5AP2 RNA expression–survival associations across cancer types. High OR5AP2 expression shows unfavorable associations in ACC, KIRC, PAAD, LIHC, COAD and BLCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for OR5AP2 RNA expression.
This table summarizes OR5AP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for OR5AP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR5AP2 shows lower tumor expression in BRCA. The BRCA box plot shows higher OR5AP2 RNA expression in normal versus tumor tissue (log2 FC = −0.006, t-test p = .022).
This table shows molecular features associated with OR5AP2 in patient tissues and cancer cell lines. In patient samples, OR5AP2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, OR5AP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
